Infection Control Today Magazine

Vancomycin

Dificid Poised to Challenge Vancomycin Usage in the Treatment of Clostridium difficile Infection

Arlington Medical Resources (AMR) and BioTrends Research Group find that less than half of surveyed infectious disease (ID) specialists and only 6 percent of surveyed internists demonstrated unaided awareness of and familiarity with Dificid prior to its U.S. launch in ...More
September 12, 2011
Posted in News, Infections & Pathogens
Scientists Re-engineer an Antibiotic to Overcome Resistant Bacteria

A team of scientists from The Scripps Research Institute have successfully reengineered an important antibiotic to kill the deadliest antibiotic-resistant bacteria. The compound could one day be used clinically to treat patients with life-threatening and highly resistant ...More
August 24, 2011
Posted in News, Infections & Pathogens
Survey Shows Vancomycin Continues to Dominate MRSA Treatment

According to surveyed infectious disease specialists and internists as well as hospital patient-level medical data, Decision Resources and Arlington Medical Resources (AMR) find that vancomycin—which has experienced increasing usage over the past five years—continues to ...More
May 23, 2011
Posted in News
Penn State, Ganeden Biotech Present New Data on Probiotic and C. diff

Ganeden Biotech announces that the company will present new in vivo data on the effect of its GanedenBC30 probiotic strain in C. diff infection at the Digestive Disease Week (DDW) conference in Chicago, being held May 7-10, 2011. Jointly with its collaborator, Dr. Leo R. ...More
May 4, 2011
Posted in News
Researchers Study Fecal Pharmacokinetics of Oral Vancomycin for Suspected C. diff Infection

Oral vancomycin (125 mg qid) is recommended as treatment of severe Clostridium difficile infection (CDI). Higher doses (250 or 500 mg qid) are sometimes recommended for patients with very severe CDI, without supporting clinical evidence. Milagros Gonzales, of the Department ...More
January 3, 2011
Posted in News
Study Shows Higher Rates of Success for Zyvox Versus Vancomycin in MRSA Nosocomial Pneumonia

Results of a new international phase 4 study of patients with nosocomial pneumonia due to proven methicillin-resistant Staphylococcus aureus (MRSA) demonstrated that the antibiotic Zyvox® (linezolid) achieved a statistically significantly higher clinical success rate ...More
October 26, 2010
Posted in News
Vancomycin is the Drug of Choice for Treating Cellulitis

Patients admitted to the hospital for the common bacterial skin infection cellulitis should be treated as a first line of defense with the potent antibiotic drug vancomycin rather than other antibiotics such as penicillin, according to a Henry Ford Hospital study. For some ...More
October 25, 2010
Posted in News
Study Shows hVISA Linked to High Mortality

A MRSA infection with a reduced susceptibility to the potent antibiotic drug vancomycin is linked to high mortality, according to a Henry Ford Hospital study. Researchers found that patients who contracted a MRSA infection with heteroresistance, called hVISA, stayed in the ...More
September 13, 2010
Posted in News